$A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial$
Código QR

A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial

Khaled Hamdi Elbaklish, Wael Adel Gomaa Ophthalmology Department, Ain Shams University, Cairo, EgyptCorrespondence: Khaled Hamdi ElbaklishOphthalmology Department, Ain Shams University, Abbasi, Cairo, EgyptTel +20 100 005 7550Email khaled.hamdy62@yahoo.comAim: To compare a range of clinical outcome...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elbaklish KH, Gomaa WA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	glaucoma-ahmed-valve-s2-fp7-iop-encapsulation Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/de53e73a0b1147f9975d697159a3982d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de53e73a0b1147f9975d697159a3982d
record_format	dspace
spelling	oai:doaj.org-article:de53e73a0b1147f9975d697159a3982d2021-12-02T07:32:59ZA One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial1177-5483https://doaj.org/article/de53e73a0b1147f9975d697159a3982d2020-03-01T00:00:00Zhttps://www.dovepress.com/a-one-year-follow-up-of-two-ahmed-glaucoma-valve-models-s2-and-fp7-for-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Khaled Hamdi Elbaklish, Wael Adel Gomaa Ophthalmology Department, Ain Shams University, Cairo, EgyptCorrespondence: Khaled Hamdi ElbaklishOphthalmology Department, Ain Shams University, Abbasi, Cairo, EgyptTel +20 100 005 7550Email khaled.hamdy62@yahoo.comAim: To compare a range of clinical outcome variables (intraocular pressure, glaucoma medications, visual acuity, and complications) between two Ahmed glaucoma valve (AGV) models (S2 and FP7).Methods: This was a prospective and randomized clinical trial. Fifty-six patients with refractory glaucoma were randomly assigned to be implanted with either a polypropylene (S2) or silicone (FP7) Ahmed glaucoma valve. The primary outcome measure was a surgical success, defined as an IOP ≤ 16 mm Hg (without medication), and guarded success, defined as a controlled IOP ≤ 16 mmHg (with medication). Failure was defined as when the IOP lay outside of the successful range on two consecutive visits (> 16 mmHg, despite medication).Results: Mean follow-up period was 398.42 ± 12.34 days (range, 380– 420 days) for the S2 group and 401.75 ± 9.78 days (range, 385– 420 days) for the FP7 group; these values were not significantly different (P = 0.27). After 12 months of follow-up, the baseline IOP (45.42 mmHg) fell significantly to 16.14 mmHg in the S2 group (p <  0.000); there was also a significant reduction in IOP in the FP7 group (from 44.17 mmHg to 15.18 mmHg in FP7 group, p < 0.000). At the last follow-up examination, the mean IOP in the S2 group was 16.14 ± 3.18 mmHg, while that of the FP7 group was 15.18 ± 2.75 mmHg; there was no significant difference between the two groups with this respect (p = 0.23). The mean number of medications used by patients in the S2 and FP7 groups was 2.92 ± 1.27 and 2.75 ± 1.43, respectively; there was no significant difference between the two groups with this respect (p = 0.32). There was no significant difference between the FP7 and S2 groups with regard to their relative success rate (17.89% [5/28] versus 10.7% [3/28], respectively; p = 0.38).Conclusion: Our data show that the S2 and FP7 models of AGV were both effective in lowering IOP and reducing the need for glaucoma medications. Although these two AGV models had similar dimensions, they were constructed from different materials. However, there were no significant clinical differences between the S2 and FP7 AGV groups after 12 months of follow-up. Furthermore, our data indicate that bleb encapsulation was the primary factor responsible for failure rate and the need for glaucoma medication in both the S2 and FP7 groups. Our analysis further indicates that the S2 and FP7 Ahmed valves are associated with a high risk of failure when considered as a first-line therapy for cases experiencing trabeculectomy.Clinical Trial Registration: NCT04214847.Keywords: Ahmed glaucoma valve, S2, FP7, IOP, encapsulationElbaklish KHGomaa WADove Medical Pressarticleglaucoma-ahmed-valve-s2-fp7-iop-encapsulationOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 693-705 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	glaucoma-ahmed-valve-s2-fp7-iop-encapsulation Ophthalmology RE1-994
spellingShingle	glaucoma-ahmed-valve-s2-fp7-iop-encapsulation Ophthalmology RE1-994 Elbaklish KH Gomaa WA A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial
description	Khaled Hamdi Elbaklish, Wael Adel Gomaa Ophthalmology Department, Ain Shams University, Cairo, EgyptCorrespondence: Khaled Hamdi ElbaklishOphthalmology Department, Ain Shams University, Abbasi, Cairo, EgyptTel +20 100 005 7550Email khaled.hamdy62@yahoo.comAim: To compare a range of clinical outcome variables (intraocular pressure, glaucoma medications, visual acuity, and complications) between two Ahmed glaucoma valve (AGV) models (S2 and FP7).Methods: This was a prospective and randomized clinical trial. Fifty-six patients with refractory glaucoma were randomly assigned to be implanted with either a polypropylene (S2) or silicone (FP7) Ahmed glaucoma valve. The primary outcome measure was a surgical success, defined as an IOP ≤ 16 mm Hg (without medication), and guarded success, defined as a controlled IOP ≤ 16 mmHg (with medication). Failure was defined as when the IOP lay outside of the successful range on two consecutive visits (> 16 mmHg, despite medication).Results: Mean follow-up period was 398.42 ± 12.34 days (range, 380– 420 days) for the S2 group and 401.75 ± 9.78 days (range, 385– 420 days) for the FP7 group; these values were not significantly different (P = 0.27). After 12 months of follow-up, the baseline IOP (45.42 mmHg) fell significantly to 16.14 mmHg in the S2 group (p <  0.000); there was also a significant reduction in IOP in the FP7 group (from 44.17 mmHg to 15.18 mmHg in FP7 group, p < 0.000). At the last follow-up examination, the mean IOP in the S2 group was 16.14 ± 3.18 mmHg, while that of the FP7 group was 15.18 ± 2.75 mmHg; there was no significant difference between the two groups with this respect (p = 0.23). The mean number of medications used by patients in the S2 and FP7 groups was 2.92 ± 1.27 and 2.75 ± 1.43, respectively; there was no significant difference between the two groups with this respect (p = 0.32). There was no significant difference between the FP7 and S2 groups with regard to their relative success rate (17.89% [5/28] versus 10.7% [3/28], respectively; p = 0.38).Conclusion: Our data show that the S2 and FP7 models of AGV were both effective in lowering IOP and reducing the need for glaucoma medications. Although these two AGV models had similar dimensions, they were constructed from different materials. However, there were no significant clinical differences between the S2 and FP7 AGV groups after 12 months of follow-up. Furthermore, our data indicate that bleb encapsulation was the primary factor responsible for failure rate and the need for glaucoma medication in both the S2 and FP7 groups. Our analysis further indicates that the S2 and FP7 Ahmed valves are associated with a high risk of failure when considered as a first-line therapy for cases experiencing trabeculectomy.Clinical Trial Registration: NCT04214847.Keywords: Ahmed glaucoma valve, S2, FP7, IOP, encapsulation
format	article
author	Elbaklish KH Gomaa WA
author_facet	Elbaklish KH Gomaa WA
author_sort	Elbaklish KH
title	A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial
title_short	A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial
title_full	A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial
title_fullStr	A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial
title_full_unstemmed	A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial
title_sort	one-year follow-up of two ahmed glaucoma valve models (s2 and fp7) for refractory glaucoma: a prospective randomized trial
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/de53e73a0b1147f9975d697159a3982d
work_keys_str_mv	AT elbaklishkh aoneyearfollowupoftwoahmedglaucomavalvemodelss2andfp7forrefractoryglaucomaaprospectiverandomizedtrial AT gomaawa aoneyearfollowupoftwoahmedglaucomavalvemodelss2andfp7forrefractoryglaucomaaprospectiverandomizedtrial AT elbaklishkh oneyearfollowupoftwoahmedglaucomavalvemodelss2andfp7forrefractoryglaucomaaprospectiverandomizedtrial AT gomaawa oneyearfollowupoftwoahmedglaucomavalvemodelss2andfp7forrefractoryglaucomaaprospectiverandomizedtrial
_version_	1718399370881138688

A One-Year Follow-Up of Two Ahmed Glaucoma Valve Models (S2 and FP7) for Refractory Glaucoma: A Prospective Randomized Trial

Ejemplares similares